Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis

Abstract

BackgroundChronic obstructive pulmonary disease (COPD) is a chronic respiratory condition characterised by persistent respiratory symptoms and airflow limitation. Acute exacerbations punctuate the natural history of COPD and are associated with increased morbidity and mortality and disease progression. Chronic airflow limitation is caused by a combination of small airways (bronchitis) and parenchymal destruction (emphysema), which can impact day-to-day activities and overall quality of life. In carefully selected patients with COPD, long-term, prophylactic use of antibiotics may reduce bacterial load, inflammation of the airways, and the frequency of exacerbations. ObjectivesTo assess effects of different prophylactic antibiotics on exacerbations, quality of life, and serious adverse events in people with COPD in three separate network meta-analyses (NMAs), and to provide rankings of identified antibiotics. Search methodsTo identify eligible randomised controlled trials (RCTs), we searched the Cochrane Airways Group Specialised Register of trials and clinical trials registries. We conducted the most recent search on 22 January 2020. Selection criteriaWe included RCTs with a parallel design of at least 12 weeks' duration evaluating long-term administration of antibiotics prophylactically compared with other antibiotics, or placebo, for patients with COPD. Data collection and analysisThis Cochrane Review collected and updated pair-wise data from two previous Cochrane Reviews. Searches were updated and additional studies included. We conducted three separate network meta-analyses (NMAs) within a Bayesian framework to assess three outcomes: exacerbations, quality of life, and serious adverse events. For quality of life, we collected data from St George's Respiratory Questionnaire (SGRQ). Using previously validated methods, we selected the simplest model that could adequately fit the data for every analysis. We used threshold analysis to indicate which results were robust to potential biases, taking into account each study's contributions to the overall results and network structure. Probability ranking was performed for each antibiotic class for exacerbations, quality of life, and serious adverse events.Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis (Review)

Network meta‐analyses in psoriasis: overview and critical discussion

“…Network meta-analyses have gained great importance in therapeutic research wherever a large number of CTs on different drugs are to be correlated. [5][6][7][8][9] This is currently particularly true in psoriasis, where a large number of approved drugs means that it is no longer possible to conduct complete clinical research with direct comparisons. Multiple comparisons are therefore used via bridge operators to create a comparable data situation.…”

“…It consists of an evidence‐based set of items in the form of a checklist and a flow diagram 4 . NMAs have been published in different medical fields like cardiovascular diseases and diabetes, 5 pneumology 6 and psychiatry 7 . Also, interventions other than drug treatments were investigated, such as exercise in Alzheimer's disease 8 .…”

The lung microbiome: progress and promise

“…It is associated primarily with smoking, though additional factors are indoor smoke exposure, pollution, early-life respiratory infections, and genetics (87). Bacteria can be isolated by culture from sputum and BALF during exacerbations (88)(89)(90), and prophylactic macrolide antibiotics reduce exacerbations in advanced disease (91), implicating microbial drivers.…”

Informatic analysis of the pulmonary microecology in non-cystic fibrosis bronchiectasis at three different stages

“…Non-cystic fibrosis bronchiectasis (nCFB) is a chronic pulmonary disease characterized pathologically by permanent dilation and chronic inflammation of the bronchi and bronchioles and clinically by chronic progressive cough and hemoptysis dyspnoea and exacerbated recurrent infection [ 1 ]. It is the final common pathway through which various inflammatory, hereditary, autoimmune, developmental, and allergic diseases funnel [ 2 , 3 , 4 , 5 , 6 ]. Compared to patients without nCFB, those with nCFB have higher all-cause-, respiratory- and lung cancer-related mortalities.…”